Navigation Links
Onconova Therapeutics Announces Presentation of Clinical and,Non-Clinical Results for Its Lead Compound ON 01910.Na at American,Association of Cancer Research Conference in Los Angeles

LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Apr 16, 2007 - Onconova Therapeutics, Inc. today announced the presentation of several scientific studies relating to its lead anticancer drug ON 01910.Na at the Annual Meeting of the American Association for Cancer Research (AACR) being held April 14-18, 2007 in Los Angeles, California. During this meeting, on Sunday, April 15th, Dr. E. Premkumar Reddy, the scientific founder of Onconova was honored as the recipient of the 2006-2007 Society of Asian American Scientists in Cancer Research Award for his fundamental contributions to cancer research.

Data presented in oral and poster sessions will focus on pre-clinical and clinical studies with ON 01910.Na, a novel, targeted, small-molecule anti-cancer compound undergoing multiple clinical trials at several major clinical centers in the USA and abroad. ON 01910.Na has shown broad-spectrum anti-tumor activity against both solid tumors and hematological malignancy in pre-clinical studies, and has demonstrated synergistic activity when combined with several classes of conventional chemotherapeutic agents. The Company is planning multiple Phase 2 and combination Phase I clinical trials with leading investigators at major oncology clinical centers in the USA.

The antitumor activity of ON 01910.Na in combination with Eloxatin(R) (Sanofi-Aventis) is demonstrated in a poster presentation entitled, "ON 01910.Na enhances the in vivo cancercidal effects of Oxaliplatin" by J. Jiang, Y. Li, L. Wang, J. Qu, P. Mannam, E. P. Reddy and James F. Holland (Mount Sinai School of Medicine, New York). Employing a nude mouse model system and human liver, hormone refractory prostate, melanoma, pancreatic and colon tumors, single agent activity of ON 01910.Na was shown for all tumor types tested and this effect was enhanced by combining with Oxaliplatin in the liver, prostate and melanoma tumor models. ON 01910.Na was well tolerated in all case
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:8/28/2014)... Aug. 28, 2014  In anticipation of the upcoming ... made available for the first time. Industry Overview: Medtech ... offers a snapshot of San Diego,s ... everything from the latest employment statistics to current venture capital ... San Diego such a vital part of the ...
(Date:8/28/2014)... , Aug. 28, 2014 Levi & Korsinsky ... in the United States District Court for the District ... investors who purchased Galectin Therapeutics Inc. ("Galectin" or the ... July 28, 2014. For more information, click ... that during the Class Period the Company violated federal ...
(Date:8/28/2014)... , Aug. 28, 2014   Edison ... today announced a worldwide search for product ideas ... senior population.  Promising ideas uncovered through the 6-month ... leading medical device manufacturers and healthcare retailers with ... the lives of individuals age 65 and older. ...
Breaking Medicine Technology:New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 3
(Date:8/28/2014)... Millennium Treatment Group is excited ... month will be a celebration of the positive ... Along with other treatment facilities and mental health ... the word about this national observance. , National ... of treatment and recovery professionals, and has since ...
(Date:8/28/2014)... Millennium Treatment Group has noticed a recent ... A recent report from the National Council on ... abuse is costing employers an estimated $81 billion every ... drugs affect their employers and the company they work ... causing expensive problems for their employers, such as lost ...
(Date:8/28/2014)... HealthDay Reporter THURSDAY, Aug. 28, 2014 (HealthDay ... symptoms of multiple sclerosis (MS), a new study from Argentina ... D, smoking and Epstein Barr virus infection. Our study shows ... MS patients," said lead researcher Dr. Mauricio Farez, of the ... Multiple sclerosis is a disease of the nervous system that ...
(Date:8/28/2014)... 28, 2014 Testimony began this ... a transvaginal mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ )involving ... LLP reports. Court documents pending in the U.S. ... that the case was filed on behalf of ... surgeries, allegedly due to vaginal mesh complications associated ...
(Date:8/28/2014)... 28, 2014 Allegheny Health ... a regional partnership designed to advance sports nutrition ... competitive young athletes, scholastic athletes and their families ... Body & Mind Initiative will offer a comprehensive ... physical and mental dynamics involved in pursuing athletic ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Celebrates National Recovery Month 2Health News:Drug Use Causes Problems in the Workplace 2Health News:Could Too Much Salt Harm MS Patients? 2Health News:Could Too Much Salt Harm MS Patients? 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 3Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 4
... the most common disorder seen in diabetics. New research shows ... diabetes develops diabetic retinopathy,// a major cause of blindness for ... for 7 percent of legal blindness, making it the leading ... 70 years old. ,Researchers from the Texas studied more ...
... can block the death of brain cells in mice who ... (HD), which is a rare degenerative brain disorder //caused by ... may be one step closer to a treatment, according to ... treated with a bile acid known as tauroursodeoxycholic acid (TUDCA), ...
... diabetes who are in a happy marriage have better ... Researchers from the State University of New York Medical ... who had been married for an average of 21 ... again two years after the initial survey. ...
... Boston, a person's degree of inhibition when it comes to ... or her likelihood of being overweight. The good news is ... people who just can't seem to resist the temptation to ... reasons why some people are able to stay trim while ...
... been found that there are ways to keep your mental ... specific part of life. The older population is growing rapidly ... think, learn and judge, known as cognitive ability, is essential ... from the Institute for the Study of Aging in New ...
... widely spread cancer all over the world. More than ... die from breast cancer this year. Researchers now believe ... important factor fueling this ever-growing epidemic.// ,Researchers ... that included information on breastfeeding and childbearing patterns. Together, ...
Cached Medicine News:Health News:Stop and think before you eat 2Health News: Breastfeeding may decrease Breast Cancer Risk 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: